Individualized Induction Therapy for Non-elderly AML Patients With Adverse Risk Features
Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Individualized induction therapy will be applied to the non-elderly AML patients with adverse
genetic risk features guided by rapid screening with fluorescence in situ hybridization
(FISH) and next-generation sequencing (NGS), such as the combination of venetoclax plus
decitabine, and Sorafenib for patients with high (FMS-like tyrosine kinase 3-internal tandem
duplication) FLT3-ITD allelic ratio. This study aims to improve induction therapy for
non-elderly AML patients with adverse genetic risk features, reduce treatment-related
complications, and improve overall survival.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University